Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

被引：2
|
作者：
Zipp, Lisa
Saliba, Rima M.
Valverde, Rosamar [1 ]
Okoroji, Grace-Julia
Korbling, Martin
Samuels, Barry I.
Abruzzo, Lynne V. [2 ]
Alousi, Amin M.
Andersson, Borje S. [1 ]
Hosing, Chitra M.
Erwin, Bill
Anderlini, Paolo [1 ]
Popat, Uday R.
Kebriaei, Partow
Macapinlac, Homer A.
Champlin, Richard [1 ]
Khouri, Issa F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2005.2005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：875 / 876
页数：2
相关论文
共 50 条
  • [31] 90YTTRIUM IBRITUMOMAB TIUXETAN (ZEVALIN) COMBINED WITH BEAM (Z-BEAM) CONDITIONING REGIMEN PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. A GELA PHASE II PROSPECTIVE STUDY
    Gisselbrecht, C.
    Decaudin, D.
    Mounier, N.
    Tilly, H.
    Ribrag, V.
    Sebban, C.
    Milpied, N.
    Morschhauser, F.
    Coiffier, B.
    Le Gouill, S.
    Lederlin, P.
    Delarue, R.
    Laurent, G.
    Bosly, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 418 - 418
  • [32] High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Hamadani, Mehdi
    Benson, Don M., Jr.
    Lin, Thomas S.
    Porcu, Pierluigi
    Blum, Kristie A.
    Devine, Steven M.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (06) : 425 - 431
  • [33] Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation
    Wondergem, Marielle J.
    Zijlstra, Josee M.
    de Rooij, Madelon
    Visser, Otto J.
    Huijgens, Peter C.
    Zweegman, Sonja
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (03) : 395 - 397
  • [34] Clinical outcomes of post-remission therapy using 90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma
    Eun Ji Han
    Sung-Eun Lee
    Sung Hoon Kim
    Hyung Sun Sohn
    Seung Eun Jung
    Gyeongsin Park
    Byung-Ock Choi
    Sang-Nam Lee
    Suk-Woo Yang
    Kyungja Han
    Seok-Goo Cho
    Annals of Hematology, 2011, 90 : 1075 - 1082
  • [35] Updated Results of Rituximab Pre- and Post-BEAM with or without 99Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
    Chahoud, Jad
    Sui, Dawen
    Erwin, William D.
    Gulbis, Alison M.
    Korbling, Martin
    Zhang, Mingzhi
    Ahmed, Sairah
    Alatrash, Gheath
    Anderlini, Paolo
    Ciurea, Stefan O.
    Oran, Betul
    Fayad, Luis E.
    Bassett, Roland L., Jr.
    Jabbour, Elias J.
    Medeiros, L. Jeffrey
    Macapinlac, Homer A.
    Young, Ken H.
    Khouri, Issa F.
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2304 - 2311
  • [36] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
  • [37] 90YTTRIUM ZEVALIN FOLLOWED BY BEAM (Z-BEAM) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR THE TREATMENT OF HIGH RISK RELAPSED/RESISTANT AGGRESSIVE NON HODGKIN'S LYMPHOMA (NHL)
    Botto, B.
    Ciochetto, C.
    Bello, M.
    Passera, R.
    Benevolo, G.
    Boccomini, C.
    Chiappella, A.
    Freilone, R.
    Giunta, F.
    Nicolosi, M.
    Novelli, R.
    Orsucci, L.
    Pecoraro, C.
    Pregno, P.
    Riccomagno, P.
    Tonso, A.
    Bisi, G.
    Vitolo, U.
    HAEMATOLOGICA, 2012, 97 : 96 - 96
  • [38] Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial
    Briones, Javier
    Novelli, Silvana
    Garcia Marco, Jose Antonio
    Francisco Tomas, Jose
    Bernal, Teresa
    Grande, Carlos
    Canales, Miguel
    Torres, Antonio
    Moraleda, Jose M.
    Panizo, Carlos
    Palmero, Fernanda
    Jarque, Isidro
    Hernandez, Miguel
    Gonzalez Barca, Eva
    Lopez, Dulce
    Caballero, Dolores
    BLOOD, 2012, 120 (21)
  • [39] RITUXIMAB WITH DOSE-DENSE MEGACEOP AND HIGH DOSE CHEMOTHERAPY (HDC) R-MAD WITH BEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN UNTREATED HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Chiappella, A.
    Tucci, A.
    Cabras, M. G.
    Liberati, A. M.
    Salvi, F.
    Ciccone, G.
    Angelucci, E.
    Badone, M.
    Botto, B.
    Falchi, L.
    Frairia, C.
    Freilone, R.
    Novero, D.
    Orsucci, L.
    Pavone, V.
    Pogliani, E. M.
    Ricardi, U.
    Rossi, G.
    Rota-Scalabrini, D.
    Levis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 305 - 306
  • [40] Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
    Gisselbrecht, Christian
    Schmitz, Norbert
    Mounier, Nicolas
    Gill, Devinder Singh
    Linch, David C.
    Trneny, Marek
    Bosly, Andre
    Milpied, Noel J.
    Radford, John
    Ketterer, Nicolas
    Shpilberg, Ofer
    Duehrsen, Ulrich
    Hagberg, Hans
    Ma, David D.
    Viardot, Andreas
    Lowenthal, Ray
    Briere, Josette
    Salles, Gilles
    Moskowitz, Craig H.
    Glass, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) : 4462 - 4469
12345